William Trost
Psychiatry · Danville, VANPI 1528025822
Payments from drug & device makers
Across 99 payments — averaging $18.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$375
- AbbVie$236
- Alkermes, Inc.$229
- Otsuka America Pharmaceutical, Inc.$192
- Teva Pharmaceuticals USA, Inc.$160
- Neurocrine Biosciences, Inc.$110
- plus $533 from 13 others
What the payments were for
- Food & beverage$1,74895%
- Education$885%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 21 | $375 |
| AbbVie(2 entities) | 13 | $236 |
| Alkermes, Inc. | 12 | $229 |
| Otsuka America Pharmaceutical, Inc. | 10 | $192 |
| Teva Pharmaceuticals USA, Inc. | 7 | $160 |
| Neurocrine Biosciences, Inc. | 6 | $110 |
| Axsome Therapeutics, Inc. | 5 | $109 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $77 |
| Lundbeck LLC | 3 | $76 |
| E.r. Squibb & Sons, L.L.C. | 3 | $72 |
| Sunovion Pharmaceuticals Inc. | 5 | $39 |
| Indivior Inc. | 2 | $31 |
| Biogen | 1 | $23 |
| Corium, LLC | 1 | $22 |
| Novo Nordisk | 1 | $19 |
| Lilly USA, LLC | 1 | $18 |
| Dexcom, Inc. | 1 | $17 |
| Noven Therapeutics, LLC | 1 | $17 |
| MDD US Operations, LLC | 1 | $12 |
How this compares
$1,836 in reported general payments places this provider in the 80th percentile of 884 psychiatry providers in Virginia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 52 | $87,878 |
| CaplytaLumateperone Tosylate | 17 | $27,007 |
| RexultiBrexpiprazole | 13 | $22,209 |
| LybalviOlanzapine/Samidorphan Malate | 12 | $19,065 |
| Lurasidone Hcl | 76 | $18,515 |
| QuviviqDaridorexant Hcl | 15 | $7,621 |
| Varenicline Tartrate | 25 | $7,330 |
| Aripiprazole | 110 | $6,503 |
| BelsomraSuvorexant | 14 | $5,869 |
| Duloxetine Hcl | 126 | $2,424 |
| Hydroxyzine Hcl | 100 | $2,215 |
| Quetiapine Fumarate | 138 | $2,015 |
| Paliperidone ErPaliperidone | 20 | $1,884 |
| Olanzapine | 78 | $1,867 |
| Carbamazepine | 21 | $1,747 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $236 | $87,87852 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $77 | $27,00717 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $192 | $22,20913 claims |
| Alkermes, Inc.Lybalvi | $229 | $19,06512 claims |
| Lilly USA, LLCOlanzapine | $18 | $1,86778 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 884 psychiatry providers in Virginia.
Other psychiatry in Danville
- Kanchan ClarkDanville$16K
- Donovan ClarkDanville$14K
- Niku SinghFalls Church$2.5M
- David ScheidererRoanoke$2.4M
- Kent McDanielGlen Allen$2.1M
- Jasdeep MiglaniManassas$958K
- Frederick MoellerRichmond$678K
- David SpiegelNorfolk$565K
- Christopher van EyckStafford$392K
- Anita ClaytonCharlottesville$356K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.